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ABSTRACT 
cGMP-dependent protein kinases (PKG) are key players in intracellular second 
messenger signaling within many cellular systems throughout the body. Most notably 
PKG is known for its role in smooth muscle relaxation (Pfeiffer et.al, 1999). The Iα PKG 
isozyme has been identified as the primary effector of the nitric oxide pathway (and 
serves to be a novel drug target). To date the overall knowledge of structure and function 
of PKG is lacking in terms of the mechanisms of activation and the structural 
orientations that coordinate them. Recently, our laboratory has solved the crystal 
structure of the regulatory domain of PKG Iα, which revealed a previously unknown α-
helical domain dubbed the Switch Helix (SW) (Osborne et.al, 2011). The SW domain was 
found to be a site of interprotomer communication via hydrophobic interactions between 
its C-terminus and hydrophobic residues, named the nest located on the opposing 
protomer. Synthetic peptides derived from the SW domain, named S-tides, dose-
dependently activate PKG Iα (Moon et.al, 2015). In addition, the amino acid residues of 
the nest are in proximity to the cGMP binding site B. It was hypothesized that the 
binding site for S-tides (nest) and the cGMP binding site B interact and are co-dependent 
of one another. 
The hypothesis of this thesis is the binding site for the S-tides (nest) and the 
cGMP binding site B interact and are co-dependent of one another. To test this 
hypothesis two aims were constructed: Aim 1: To develop an S1.5 analog that utilizes 
both the nest and the B-site to increase S-tide activity, Aim 2: To explore the intricacies 
of these modes of activation and how they interact with each other to obtain a better 
understanding of the interplay between these two sites. First, based on the most potent 
S-tide S1.5 (YEDAEAKAKYEAEAAFFANLKLSD, Ka=6 µM), two analogs were 
synthesized. The peptide S2.5 which lacked the amino acids LSD at the C-terminus 
showed a three-fold lower activation constant (Ka= 15 µM), although the molecule 
retained its helicity as demonstrated by circular dichroism. The second analog, S3.5 
contained unnatural amino acid components from a molecular modeling approach in an 
effort to further increase the affinity by interacting with the adjacent cGMP binding site 
B. However, S3.5 showed further reduction in activity with an activation constant of 70 
µM. These findings led us to conclude that the failure of the SAR approach indicates a 
different mode of S-tide activation as had been previously thought. Next, we investigated 
the role of the cGMP binding site B in the mechanism of S-tide mediated PKG Iα 
activation. Co-activation assays with cGMP and S1.5 demonstrated that cGMP activation 
is not altered in the presence of S1.5. Furthermore, S1.5 mediated activation is negatively 
affected in the presence of cGMP. These results suggest that the B-site of cGMP does not 
positively enforce the S1.5 activation kinetics.  Next, we employed the PKG Iα mutant 
E292A, which cannot bind cGMP to the B-site (Moon et.al., 2018). Interestingly, this 
mutant retains the activation kinetics of PKG Iα WT when activated via S1.5 and cGMP. 
Thus, the cGMP binding site B is not crucial in the activation mechanisms of activating 
PKG Iα with cGMP. Likewise, the cGMP binding site B is not crucial in the activation 
mechanisms of activating PKG Iα with S1.5. To further support these findings, the PKG 
Iα mutant C42A, which showed crippled cGMP activation kinetics could be activated 
with S1.5 with a potency similar to wild type.  
Taken together, the results in this thesis demonstrate that in contrast to the 
initial hypothesis the binding sites for S-tides and cGMP, although in proximity, show no 
experimental support of a positive interaction. These findings are significant as they 
reveal that S1.5 mediated activation of PKG is truly independent of cGMP, thereby 
providing a molecular platform for the therapeutic development of these unique 
peptides.  
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1.0 INTRODUCTION 
1.1 Genetic Overview of PKG 
Protein Kinases are a family of enzymes that are responsible for protein 
phosphorylation, an extremely important cellular mechanism for transmitting 
information through cells. The human kinome consists of over 500 known kinases spilt 
into several distinct groups (Manning et al., 2002). The cGMP-dependent protein kinase 
(Protein Kinase G, PKG) belongs to the AGC kinase family (Pearce et al., 2010). This 
family contains over 60 kinases but is named after three central members PKA, PKG, 
PKC (Arencibia et al., 2013). PKG, like all AGC kinases functions by transferring the γ-
phosphate of an ATP to a serine or threonine residue of a basic substrate, making these 
enzymes basophilic serine/threonine kinases (Alessi et al., 1996). As the name suggests, 
PKG is a receptor for the second messenger 3’,5’-cyclic guanosine monophosphate 
(cGMP). = 
Increased levels of intracellular cGMP activate the kinase, thereby triggering 
phosphorylation. Within mammalian cells there are three PKG isoforms coded by two 
separate genes. The gene prkg1 codes for PKG I which exists as two splice variants PKG 
Iα and PKG Iβ (Orstavik et al., 1997). The gene prkg2 codes for the third isoform PKG II 
(Gamm et al., 1995).  
The expression of these isoforms is tissue specific. The PKG Iα isoform tends to 
be expressed in the heart, lungs, cerebellum, and dorsal ganglia regions of the brain 
(Hofmann et al., 1992). The PKG Iβ isoform is expressed in the hippocampus and blood 
platelets (Geiselhoringer et al., 2004a). The expression of PKG II is widely distributed 
throughout the brain (de Vente et al., 2001). PKG is integral in the regulation of neuronal 
potentiation, platelet function and smooth muscle relaxation (Hofmann et al., 2006). 
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1.2 The Role of PKG in Smooth Muscle Relaxation  
The contraction and relaxation of vascular smooth muscle is a tightly regulated 
system that maintains homeostasis throughout the body (Wang et al., 2015). Smooth 
muscle contraction is coordinated via calcium influx into the cell triggered by receptor 
binding or mechanical stretch stimuli. The influx of calcium results in calmodulin 
binding to Ca2+ which interacts with myosin light chain kinase (MLCK) (Kuo et al., 
2015). The now active MLCK phosphorylates myosin light-chain (MLC), activating 
myosin ATPase. The activation of myosin ATPase initiates the crossbridge cycle and 
causes muscle contraction (Horowitz et al., 1996). Smooth muscle contraction is 
inhibited by myosin light-chain phosphatase (MLCP) which dephosphorylates the 
myosin (Morgado et al., 2012).  
PKG is a key enzyme in smooth muscle relaxation and is the main downstream 
effector of nitric oxide (NO) signaling. The NO pathway is initiated by NO production in 
the endothelial layer of blood vessels. NO freely diffuses into the adjacent smooth muscle 
cells and binds soluble guanylyl cyclase (sGC). Activation of sGC causes the enzyme to 
convert guanosine tris-phosphate (GTP) to cGMP (Derbyshire and Marletta, 2009) 
(Figure 1.1). The increased levels of cGMP activate PKG which causes smooth muscle 
relaxation in several ways but mainly through a decrease in intracellular Ca2+ (Hofmann, 
2005). Alterations of intracellular Ca2+ via PKG is achieved in a few ways. The first 
mechanism decreases intracellular Ca2+ through the phosphorylation of inositol 
triphosphate receptor-associated cGMP kinase substrate (IRAG), this forms a complex 
with the inositol triphosphate receptor (IP3R) which inhibits the flow of Ca2+ from the 
sarcoplasmic reticulum (SR) (Casteel et al., 2008). Another substrate for PKG that 
decreases intracellular Ca2+ is RGS2 (regulator of G-protein signaling 2), this is an 
indirect action because phosphorylation of RGS2 results in a decrease of G-protein based 
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IP3 synthesis (Kehrl et al., 2002). The decrease in IP3 reduces the activation of the IP3 
receptor and therefore Ca2+ release (Sun et al., 2005). Phospholamban (PLN) is also 
phosphorylated by PKG, when PLN is phosphorylated it stops the inhibiting the SR Ca2+-
ATPase (SERCA) and allows it to pump Ca2+ to the SR, decreasing the level of 
intracellular calcium (Lalli et al., 1999).  
PKG can phosphorylate Kca 1.1 channel causing a efflux of K+ ions and cellular 
hyperpolarization which inhibits the L-type Ca2+ channels from increasing intracellular 
calcium levels (Bolotina et al., 1994). Activation of PKG also effects phosphorylation of 
myosin in a more direct manner by enhancing the function of MLCP through inhibition 
of Ras homolog gene family member A (RhoA) and activation of Myosin phosphatase 
target subunit 1 (MYPT1). The phosphorylation of MYPT1 directly causes MLCP 
dephosphorylation of the myosin head (Wooldridge et al., 2004). Phosphorylation of 
RhoA inhibits the activating of an effector protein that phosphorylates the targeting 
region of MYPT1 that would inhibit binding to myosin and dephosphorylation. (Shin et 
al., 2002) 
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Figure 1.1. PKG’s role in vascular smooth muscle relaxation. 
The vascular smooth muscle signaling pathways controlled by PKG displayed in a 
simplified manner. The direct activations are depicted by solid lines and arrows, and the 
direct inhibitions are depicted by solid lines with solid perpendicular lines. The indirect 
actions are depicted by dotted lines. Abbreviations; soluble guanylyl cyclase: sGC, 
Phosphodiesterase 5: PDE5, Regulator of G-protein signaling 2: RGS2, inositol 
triphosphate receptor-associated cGMP-kinase substrate: IRAG, Phospholamban: PLN, 
Ras homolog gene family member A: RohA, Myosin Light Chain Kinase and 
Phosphorylase: MLCK and MLCP, Calcium Activated Potasium channel: BKCa. 
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1.3 The Architecture of cGMP- Dependent Protein Kinase Type I 
The general organization of PKG’s domains is conserved amongst all isoform. 
PKG exists as a parallel homodimer (Huggins et at., 1994). PKG 1α and PKG 1β consists 
of 671 and 686 amino acids, with molecular weights of 153 kDa and 156 kDa respectively 
(Wernet er al., 1989). These isoforms share sequence homology in their regulatory and 
catalytic domains and vary in their dimerization and autoinhibitory domains which has 
been shown to affect their activation and substrate targeting (Orstavik et al., 1992, 1997; 
Casteel et al., 2010; Qin et al., 2015; Ruth et al., 1991).   Located at the N-terminus of the 
protein is a dimerization domain (DD) connecting the two protomers together, followed 
by a linker region. After the linker region there is an autoinhibitory domain (AI) (aa 1-
87) connected to another linker region. The next domain is the cyclic nucleotide binding 
domain, consisting of two cGMP binding sites denoted as the high-affinity A-site (aa 87-
211) and the low affinity B-site (aa 211-329). At the C-terminus of the B-site there is a 
region called the switch helix domain (SW) (aa 329-355) which interacts with the 
opposing protomer. Proceeding the SW is the catalytic domain (aa 358-671) (Figure 
1.2).  
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Figure 1.2. PKG Iα/Iβ Holoenzyme Domain Organization 
Organization of the individual domains within the parallel homodimer of PKG Iα and Iβ. 
The dimerization domain (DD), auto-inhibitory domain (AI), High-affinity cGMP 
binding site (A-site), low-affinity cGMP binding site (B-site), switch helix (SW), and 
catalytic domain sub devided into the ATP and substrate binding regions.  
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1.4 N-terminal Dimerization Domain 
The N-terminus of PKG is home to the dimerization domain (DD) which contains 
a leucine zipper motif. The leucine zipper is an amphipathic, left-handed α-helix of two 
opposing protomers that interact and joins them together (Atkinson et al., 1991; Casteel 
et al., 2010; Qin et al., 2015). The helixes in this motif exhibit an amino acid heptad 
repeat (abcdefg) with hydrophobic residues at the a and d positions and hydrophilic 
residues at the e and g positions (O’Shea et al., 1991; Atkinson et al., 1991). The a 
positioned amino acid residues are either leucines or isoleucines, the d position can have 
a wider diversity of amino acids. In PKG 1α there are four d residues that are non-
hydrophobic amino acids (Phe7, Lys14, Lsy28, Cys42) (Qin et al., 2015). The Cys42 
residue is an integral residue in dimerization because it forms a disulfide bond with the 
opposing protomer (Monken and Gill, 1980; Schnell et al., 2005)(Figure 1.3.). The 
differences in the amino acid sequence in the leucine zipper of different isoforms results 
in alternate charge distribution, this causes them to target different substrates 
(Schlossman and Desch, 2009). This isoform specific leucine zipper sequence variation 
also results in determining their cellular localization via interaction with specific G-
Kinase-anchoring proteins (GKAPs) (Casteel et al., 2008).  
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Figure 1.3. Disulfide bond at cysteine 42 of PKG Iα’s leucine zipper motif 
(PBD 4R4L) 
Leucine zipper interaction between two opposing protomers of PKG Iα. Highlighted is 
the cysteine 42 residue of both protomers which displays the disulfide bond formed 
between the two when the protein is dimerized. 
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1.5 Autoinhibitory Domain 
Following the dimerization domain is the auto inhibitory domain (AI) of PKG. 
The AI is found at amino acid 51-68 and 66-83 in the 1α and 1β isoforms, respectively.  
This region of the enzyme has been determined to be an important part of PKG 
activation. In its inactive form the AI acts as a pseudo substrate for the catalytic domain 
causing PKG to adopt a tightly inhibited confirmation (Francis et al., 1996). The AI 
residues responsible for this autoinhibition are a glycine at residue 62 in PKG 1α and an 
alanine at residue 77 in PKG 1β found in the sequence XISAEP (Kemp et al., 1988; 
Francis et al., 1996). The precise mechanism of this inhibition has remained elusive, but 
it is most likely through the binding of the phosphate acceptor site of the catalytic region 
preventing substrate phosphorylation, a mechanism closely homologous to PKA (Francis 
et al.,1996). This inhibition mechanism is supported by the generation of a PKG Iα 
mutant with a truncation mutation to Arg77, the resulting enzyme was constitutively 
active (Heil et al., 1987; Landgraf et al., 1990; Scholten et al., 2007). Within the AI it has 
also been seen that autophosphorylation can occur in the presence of both cAMP and 
cGMP at Thr58, this is believed to cause ubiquitination and turnover of PKG Iα (Takioe 
et al., 1983; Atiken et al., 1984; Dey et al., 2009). 
 
1.6 Cyclic Nucleotide Binding Domain 
The cyclic nucleotide binding domain of PKG is responsible for regulating the 
activity of the enzyme. This domain in both PKG Iα and Iβ is structurally identical 
containing two consecutive cyclic nucleotide binding sites per protomer. Despite having 
the same structure PKG Iα and PKG Iβ have different activation kinetics. It has been 
shown that there is a 10-20 fold difference in their cGMP activation constants (Ka), PKG 
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Iα has a Ka of about 100 nM, whereas PKG Iβ has a Ka of 1-2 µM  (Ruth et al., 1991). This 
variance in activation kinetics is, thought to stem from the differences found in the 
dimerization domain (DD) and the autoinhibitory domain (AI) as well (Ruth et al., 1997).   
Within this domain the two cGMP binding sites have very different kinetics. The 
A-site is known as the high-affinity binding site and binds cGMP with a higher affinity 
than the B-site (low-affinity binding site) with binding affinities of 17 nM and 100-
150nM cGMP, respectively (Corbin et al., 1986). The amino acid residues responsible for 
binding cGMP are highly conserved so it is interesting that these two sites display 
different binding kinetics for cGMP. The difference may be a result of the theory of the 
B-site acting more as a selectivity filter for cGMP. It was initially thought that the 
selectivity filter for cGMP over cAMP was a threonine found in both sites in both 
isoforms Thr177/192 and Thr301/316 PKG Iα and Iβ respectively (Kim et al., 2011). After 
further investigation of an isolated A-site it was determined that the binding constants 
(KD) were 12 and 27 nM for cGMP and cAMP respectively showing that there is poor 
selectivity via the previous mechanism. It was demonstrated that the cyclic nucleotide 
selectivity is caused by the B-site at Arg281/296 which interact with O6 and N7 on the 
guanine, in the A-site the equivalent residue is Leu155/170 (Huang et al., 2014; Kim et 
al., 2011, 2016). 
 The holoenzyme crystal structure has yet to be solved, we only have crystal 
structures of isolated DD and regulatory domain and therefore do not have a structure 
detailing the complex interaction of the cyclic nucleotide binding sites, the N-terminal 
domains and the catalytic domain.  
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Figure 1.4 The Regulatory Domain of PKG Iα (PDB 3SHR) 
Displayed above is the regulatory domain of PKG Iα consisting of amino acids 77-326. 
The domain is split into the high affinity cGMP binding A-site and the low affinity cGMP 
binding B-site. 
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1.7 The Catalytic Domain 
The C-terminal domain of PKG is its catalytic domain (PKG 1α aa 360-671, PKG 
1β aa 375-686) responsible for binding substrate/ATP and catalyzing the 
phosphorylation reaction. Like all AGC kinases PKG transfers the γ-phosphate of ATP to 
a serine or threonine residue of the basic substrate (Alessi et al., 1996). Due to the lack of 
complete crystal structures of PKG the exact 3D conformation of this region is unknown. 
Therefore, we rely on biochemical data and the known structures of PKA and its 
sequence homology models of PKG. The crystal structures of 14 different AGC kinases 
show a conserved fold in this domain (Pearce et al., 2012; Taylor et al., 2005). The fold as 
seen in PKA show the catalytic subunit is divided into a small N-terminal lobe (N-lobe), 
responsible for binding ATP, and a large C-terminal lobe (C-lobe), containing the 
catalytic and the substrate binding region (Kim et al., 2007)(Figure 1.5). Within the N-
lobe there is a loop containing several glycine residues that bind the Mg2+ binding loop 
and ATP. This region arranges the ATPs γ-phosphate into the catalytic site for the 
phosphoryl transfer reaction. The N-lobe also functions to help create the active site by 
coordinating components of the C-lobe. The C-lobe is responsible for a majority of the 
reaction catalyzing residues. The C-lobe contains a catalytic loop containing an aspartate 
which deprotonates the substrates serine or threonine residue. Mg2+ ions are positioned 
via N-lobe residues and the activation loops DFG motif. A threonine residue (Thr197) in 
the activation loop is phosphorylated causing a conformational change aligning the N-
lobe, the activation loop and substrate binding sites to their active positions (Bastidas et 
al., 2013; Smith et al., 1999; Steichen et al., 2012). It has been shown that Thr516 on PKG 
Iα serves as the equivalent to Thr197 of PKA (Feil et al., 1995). The lack of PKG 
holoenzyme crystal structure leaves some uncertainty about the structural details of its 
13 
 
catalytic domain but sequence homology with PKA allows us to make well educated 
assumptions that suggest it functions much like the mechanisms above. 
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Figure 1.5. Catalytic domain of PKA 
Displayed is the catalytic domain of PKA which is structurally homologous to all AGC 
kinases and therefore is relevant as a model for the catalytic domain of PKG. The model 
displays the N-lobe and C-lobe of the domain top and bottom respectively. The 
catalytically relevant loops are color coded. The red loop represents the glycine rich loop. 
The yellow loop represents the catalytic loop. The orange loop represents the activation 
loop. The magenta loop represents the P + 1 loop. Within the N-loop are two Mg2+ ions 
and bound ATP, blue and salmon respectively.  
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 1.8 The Switch Helix 
Directly following the B-site a domain known as the switch helix (SW) was 
discovered through x-ray crystallography by Osborne et al. (2011) (Figure 1.4). The SW 
is an α-helix located at the junction of the regulatory and catalytic domains, amino acids 
329-355 of PKG Iα. The C-terminus of the helical switch domain consists of a series of 
hydrophobic residues (AAFFANL) called the “knob” (aa 350-345) which interacts with 
complementary hydrophobic residues of the phosphate binding cassette (PBC), the N3A, 
αB and β6 motifs from the B-site of the opposing protomer, this is called the “nest” 
(Osborne et al., 2011; Moon et al., 2013). Including the leucine zipper of the DD this SW 
domain represents one of only two sites of interprotomer interaction and 
communication.  
The effect of the switch helix on PKG activation was explored further by Moon et 
al. (2015) who found that a synthetic peptide of the same sequence of the alpha helix 
from the SW (aa 329-358) known as S-tide 1.1 (S1.1) activated PKG 1α independently of 
cGMP (Table 1.1). Following this discovery, a series of synthetic S-tides were created to 
determine the essential amino acid sequence for activation.  The C-terminal amino acids 
were analyzed for significance, removing 3 amino acids at a time two S-tides were 
created and showed that the first three could be removed without change in activity 
(S1.2), however the subsequent deletion (S1.3) resulted in an inactive peptide due to the 
absence of the knob residues. The N-terminus was then investigated in the same manner 
resulting in two S-tides with 3 and 6 amino acids removed S1.4 and S1.5 respectively. The 
truncations resulted in increased activity with as low as 3 µM S1.5 (Moon et al., 2015). 
This effect is only observed in PKG Iα and not PKG Iβ and presents the possibility of a 
PKG Iα selective novel drug target. 
16 
 
 
Figure 1.6. Switch helix domain of PKG Iα (PDB 3SHR) 
Pictured is the switch helix domain of PKG Iα as well as the cGMP A & B site of the 
regulatory domain. The two opposing protomers are denoted by green and purple and 
the various subparts of each domain are labeled with red arrows. A; represents one 
protomer of the SW and regulatory domain whereas B represents the interaction of the 
two opposing protomers 
A 
B 
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Table 1.1. S-Tide Name and sequence. 
The name of the sequences are listed in order of development on the left of the table 
followed by their corresponding sequences, activation constant (Ka) in µM concentration, 
and Hill coefficient (nH). The peptide sequences are aligned based on the position of the 
knob sequence. 
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1.9 Aims of Thesis 
The following central hypothesis and specific aims were constructed to explore 
the structure activity relationship of S-tide mediated activation with respect to the cGMP 
B-site.  
Hypothesis: The binding site for the S-tides (nest) and the cGMP 
binding site B interact and are co-dependent of one another.  
Aim 1: To develop an S1.5 analog that utilizes both the nest and the B-
site to increase S-tide activity.  
To test this, we will create two peptides derivatives of S1.5 with sequential C-
terminal modifications to probe the low affinity cGMP B-site. The first of the two 
peptides will be a three amino acid truncation that is necessary for further peptide 
modification. The second will consist of the truncated peptide with the addition of a 
cysteamine linker that should reach the B-site. The activity of these peptides will be 
tested via kinase assays. 
 Aim 2: To explore the intricacies of  cGMP and S-Tide mediated 
activation and how they interact with each other to obtain a better 
understanding of the interplay between these two sites.  
To test this, we will use of activator combination kinase assays and mutant forms 
of PKG allowing us to create a kinetics based model of the activation of each of these 
sites. The combination assays will consist of a constant concentration of cGMP with dose 
response concentrations of S1.5 and constant concentration of S1.5 with dose response 
concentrations of cGMP. To test the direct effect of the B-site interaction with the SW we 
will be testing the B-site knock out mutant (E292A). To test the overall similarity in 
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activation mechanism we will employ the C42S mutant which has a documented 
degradation of cGMP activation.  
The aim of this thesis serves to explore the structure to function relationship of 
the switch helix domain of PKG. The previous work of the Dostmann laboratory 
uncovered the structure of the switch helix domain and went further to discover the 
unique ability of synthetic peptides, derived from the switch helix, to activate the 
holoenzyme and establish the possibility for a novel drug target not before observed. 
This preliminary work warranted further exploration into the mechanics of this unique 
property of PKG. It was necessary to test the effects preincubation had on S-tide 
activation and PKG with cGMP due to the slow binding kinetics of S1.5 and the need to 
establish standard assay conditions. To further explore the possibilities of S-tides new 
derivatives of the most potent S-tide (S1.5) were created via molecular modeling with the 
rational of creating a peptide that would interact with the adjacent cGMP B-site of PKG 
Iα. The possible interaction would strengthen the activation kinetics of the S-tides. This 
portion of the thesis demanded that we construct intermediary S1.5 analogs to test the 
kinetic effect of removing the three c-terminal amino acids of S1.5 and the addition of a 
linker resulting in the new S2.5 and S3.5 peptides. To test their role, we employed 
secondary structure analysis via, circular dichroism spectroscopy, as well as kinetic 
assays. We hypothesized that the subtraction of these amino acids would not have a 
significant effect and if they did it would be due to a loss of helicity.   
Since the switch helix binding site shares amino acids with the phosphate binding 
cassette (PBC), the N3A, αB and β6 motifs from the B-site prompted us to investigate the 
interplay between cGMP and S-tide activation. We hypothesized that the mechanism of 
activation was linked. To test this, we employed activator combination assays with PKG 
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Iα WT as well as the mutant PKG Iα E292A (B-site knock-out). To test the similarity of 
the two forms of activation we employed the mutant PKG Iα C42S which has 
documented degradation of cGMP activation. This work was conducted to further our 
understanding of the switch helix and its mechanism of action. The results of this 
endeavor serve as a base for further research into the structure and function of PKG and 
its exploitation as a potential novel drug target.  
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2.0 MATERIALS AND METHODS 
2.1 Protein Expression and Purification 
2.1.1 Blue-White Screening 
 Expression of recombinant wild type and mutant bovine PKG Iα was 
accomplished using the insect cell (Sf9) Bac to Bac baculovirus expression system 
(Invitrogen). First the cDNA coding for the PKG variants was transposed from pFAST 
Bac HTA into bacmid. Approximately 50 ng of the pFAST Bac HTA containing the 
construct was added to chemically competent DH10 Bac E.coli cells. The cells were heat 
shocked at 42⁰ C for 30 seconds to allow the plasmid to enter the cells. 100 µL of Luria 
medium (Luria-Bertani or LB) was added and incubated at 37⁰C for 5 hours in the 
shaker at 220 rpm. KGTIX plates were prepared with LB agar; 50 µg/mL kanamycin; 
7µg/mL gentamicin; 10µg/mL tetracycline; 40 µg/mL isopropyl β-D-1-
thiogalactopyranoside (IPTG), and 2.4 mg of X-gal (on the surface). The E. coli were 
plated on a KGTIX plate and incubated at 37⁰C for 24 hours, followed by 4⁰C incubation 
to develop blue or white color depending on disruption of LacZ gene. Typically, white 
colonies were picked and re-streaked onto two separate KGTIX plates. This procedure 
was repeated until well separated single white colonies could be harvested for bacmid 
isolation. 
 
2.1.2 Bacmid Isolation  
Following blue-white screening, the Bacmid DNA was harvested from a single 
colony that was expressing the white phenotype which meant the gene was transposed 
into the gene that codes for β-galactosidase which would normally break down the 
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galactose from the plate and turn the colony blue. A white colony from each re-streak 
was harvested and suspended in 6 mL of LB containing 50 µg/ mL kanamycin and 7 µg/ 
mL gentamicin. The colonies were grown for 16 hours at 37⁰C and 220 rpm in the shake 
incubator. The tubes were centrifuged at 3000xg for 5 minutes, the supernatant was 
discarded, and the resulting pellet was resuspended in 300 µL of Quiagen Buffer P1 (50 
mM Tris-HCL, 10 mM EDTA, 50-100 µg/ mL RNase A, pH 8.0). The solution was 
transferred to a 1.5 mL Eppendorf tube, 250 µL of Quiagen Buffer P2 (200mM NaOH, 
1% SDS and LyseBlue indicator) was added and if lysis occurred the solution would turn 
blue. 350µL of Quaigen Buffer N3 (4.2 M guanidine hydrochloride (GuHCL), 0.9 M 
potassium acetate, pH 4.8) was added. The tubes were then centrifuged for 20 minutes 
at 15,000xg to remove cellular debris, the supernatant was transferred to a 2 mL tube 
with 800µL of 100% isopropanol, the solution was mixed via inversion, and the tubes 
were stored at -20⁰C for up to a month. The samples were then centrifuged at 15,000xg 
at 4⁰C for 30 minutes. The supernatant was decanted, and 7 washes were conducted to 
remove any remaining salt by adding 1mL of ice cold 70% ethanol to each tube and 
incubated for 10 minutes at 4⁰C, followed by 15,000xg centrifugation at 4⁰C for 10 
minutes. The supernatant was then decanted, and the pellet was air dried. The pellet was 
rehydrated with 200 µL of sterile ddH2O and stored overnight at 4⁰C. The concentration 
was determined by Nanodrop® spectrophotometry 260/280 nm and corrected to 500 
ng/µL. 
 
2.1.3 M13 PCR Bacmid Analysis 
 Following bacmid isolation, it was necessary to determine if the gene of interest 
was inserted into the E.coli, M13 PCR was employed for this determination. Each PCR 
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reaction had a total volume of 50 uL containing 150 ng of the bacmid, DreamTaq, 
200nM M13 forward primer (CCCAGTCACGACGTTGTAAAACG), 200nM M13 reverse 
primer (AGCGGATAACAATTTCACACAGG), and ddH2O. The reactions were mixed and 
then run in the thermocycler with temperatures and times determined based on the 
primers and the DreamTaq DNA polymerase (Fisher scientific) (Table. 3.1). Following 
the PCR, a 1% agarose DNA gel (Ultrapure agarose by Invitrogen) containing SYBR Safe 
stain (Thermo scientific) was run with 20 µL of each reaction and 5 µL of a 1Kb DNA 
ladder (BioLabs). The gel was run in the dark in order to preserve the florescent dye at 
100 volts for 45 minutes. the resulting band was the ladder equivalent of 2430 base pairs 
+ the inserted genes length, approximately 2,013 base pairs for PKG Iα.  
 
step Stage temperature Time (min) 
1 Hot start 95⁰C 1:30 
2 Denature 95⁰C 0:45 
3 Annealing 50⁰C 0:45 
4 Extension 68⁰C 5:00 
5 Cycle To stage 2, repeat 30x - 
6 Final extension 68⁰C 7:00 
7 Storage 4⁰C Forever 
 
Table 2.1. M13 PCR run table 
The sequence of events during M13 PCR with the corresponding temperatures and times. 
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2.1.4 Transfection and First Amplification of Baculovirus 
 Once it was determined that the gene of interest was inserted into bacmid, Sf9 
cells were transfected to produce baculovirus. Under sterile conditions, 2 mL of Sf9 cells 
at a concentration of 0.5 x 106 cells/mL in unsupplemented Sf900 III medium (Thermo 
scientific) were added to each well of a 6 well plate. The cells were allowed to adhere for 
30 minutes, followed by a media change with new unsupplemented Sf900 III medium 
(Thermo scientific). The plate was constructed with a duplicate series of the 
experimental conditions; control (0 µg), 1 µg, and 2 µg of a single Bacmid. Tubes were 
prepared for each set of wells with 300 µL of unsuplemented Sf900 III medium and their 
varying concentrations of bacmid as well as 6 µL of Cellfectin (Invitrogen). 200 µL of the 
corresponding bacmid solutions were added to each well dropwise. The plate was 
incubated for 5 hours at room temperature, followed by a media change with Sf900 III 
medium (Thermo scientific) containing 10 µg/mL gentamicin (Sigma-Aldrich), 0.01% 
poloxamer-81 (Sigma-Aldrich), and 1x lipids (Sigma-Aldrich). The plate was then 
incubated at 27⁰C and assessed every day after to determine if the cells were transfected. 
Once the cells reached late stage infection, the cells were scraped off the bottom of the 
wells and the duplicate wells were pooled. The cell samples were centrifuged at 500 x g 
for 5 minutes. The supernatant containing the virus was transferred to a dark conical and 
stored at 4⁰C until subsequent steps.  
 
2.1.5 Second Amplification of Baculovirus 
 To increase the viral titer, a second amplification was needed. 25 mL of Sf9 cells 
at a concentration of 1 x 106 cells/ mL were added to a 75 cm2 tissue culture flask and 
were allowed to adhere for 1 hour. 200 µL of the first amplification baculovirus were 
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added to the flask and incubated at 27⁰C until they reached late stage infection. The cells 
were collected and centrifuged at 500 x g and 4⁰C for 5 minutes. The supernatant was 
collected in a dark 15 mL conical, as with the first amplification virus, and then stored at 
4⁰C.  
 
2.1.6 Third Amplification of Baculovirus and Test Expression 
 A third amplification was performed to further increase the viral titer and a test 
expression was performed to determine the resulting potency of the virus. 40 mL of Sf9 
cells at a concentration of 1 x 106 cells/ mL and 2.5 mL of second amplification virus 
were added to a 125 mL baffled flask. They were incubated at 27⁰C and 80 rpm until they 
were in late stage infection. The cells were then harvested, centrifuged at 500 x g for 5 
minutes and the supernatant was transferred to a dark conical and stored at 4⁰C. To test 
the potency of the resulting baculoviral a test expression was performed with varying 
concentrations of virus and the resulting samples were subjected to a western blot to 
determine the titer and optimal infection conditions.  
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2.1.7 Expression and Purification of PKG Iα 
 Once the viral titer was determined, a full expression of PKG Iα and subsequent 
purification were performed. To a 2.8 L baffled flask, 1 L of Sf9 cells was added at the 
concentration of 1.5 x 106 cells/mL in Sf 900 III media (Thermo scientific). Baculovirus 
was then added from the third amplification at a volume of (1/500)*volume of cells. The 
cells were incubated at 27⁰C and 80 rpm for three days. The cells were then harvested, 
centrifuged at 500 x g for 30 minutes and the supernatant was discarded. 1 mL of a 10x 
protease inhibitor cocktail was added to the pellet to inhibit proteolysis of PKG. 20 mL of 
cold lysis buffer (10 mM TES Ph 7, 300 mM NaCL, 5mM imidazole) were added to re-
suspend the pellet, and the cells were lysed. The lysate was then centrifuged at 25-40K x 
g (15K RPM Sorvall SS-34 rotor) for 90 minutes at 4⁰C. While the lysate was centrifuged, 
a nickel affinity chromatography column was regenerated with the rational of (Table 
2.2). The lysate was loaded onto the column and the flow through was collected for each 
of the subsequent steps. The first wash was performed by running 7 column volumes 
(CV) of lysis buffer through the column. A second wash was then performed with 5 CV of 
mid wash buffer (10 mM TES Ph 7, 300 mM NaCl, 3mM imidazole). Once washed, an 
elution was performed by running the elution buffer (5 mM TES Ph 7, 300mM NaCl, and 
250 mM imidazole) through the column; five 5 mL fractions were collected.  Qualitative 
analysis via Bradford assay was performed by combining 20 µL of each fraction with 1 
mL of 1x Bradford reagent and the color was noted; blue indicated the presence of 
protein. Once the fractions containing the protein were identified, they were pooled. The 
pooled fractions were dialyzed in 2 L of dialysis buffer twice (50 mM MES Ph 6.9, 300 
mM NaCl, and 1mM Tcep) at 4⁰C overnight on a stir plate to exchange the buffer. A third 
dialysis was performed to exchange the buffer to the final storage buffer (50 mM MES ph 
6.9, 150 mM NaCl, 1 mM TCEP, and 10% glycerol). The resulting protein concentration 
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was determined via Nanodrop® spectrophotometry (Fischer scientific) at λ=280 nm 
with the molar coefficient of 81,250, determined by the ProtParam tool (ExPASy).   
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Solution Volume 
(CV) 
Concentration 
EDTA 10  50 mM 
ddH2O 2   
NaCl 1 1 M 
ddH2O 2  
NaOH 1 1 M 
ddH2O 10  
NiSO4 4 1 M 
Equilibration 
Buffer 
5 50 mM NaOAc, 300 mM NaCl 
ddH2O 10  
Lysis buffer 5 10 mM TES Ph 7, 300 mM NaCL, 5mM imidazole 
Cell lysate   
Wash buffer 1 7 10 mM TES Ph 7, 300 mM NaCl, 3mM imidazole 
Wash buffer 2 5 10 mM TES Ph 7, 300 mM NaCl, 3mM imidazole 
Elution buffer 6 (5 mM TES Ph 7, 300mM NaCl, and 250 mM 
imidazole 
 
Table 2.2. Nickle affinity chromatography regeneration and purification 
The sequence of events when regenerating the nickel chromatography column and 
purification of cellular lysate. The regeneration consists of the first 10 steps and the 
purification is the remaining 4 steps. At the elution, six 5mL fractions are collected. 
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2.2 Peptide Synthesis 
 The synthetic peptides (S-tides) were synthesized via solid-phase synthesis on 
Rapp S RAM resin (Rapp Polymere) with a Syro multiple peptides synthesizer 
(MultiSynTech) by Werner Tegge (Helmholtz Center for Infectious Research). Fmoc 
solid-phase synthesis was employed with tenfold excess of  2-(1H-Benzotriazole-1-yl)-
1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU) and diisopropylethyl amine 
activation. The coupling reaction was performed for 1 hour. The amino acid sidechains 
were protected with the following rational: Asp, Glu, Ser, Thr and Tyr: with a tert-butyl 
group; Asn, Cys, Gln, and His: with a Trityl group; Arg with a 2,2,4,6,7-
Pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) group; lys and Trp: with a tert-
Butyloxycarbonyl group. The resulting peptides were cleaved off the Rapp S RAM resin 
and the protecting groups were removed with a solution of Trifluoroacetic acid (TFA), 
3% triisopropylsilane and 2% water. The peptides were purified via high-performance 
liquid chromatography (HPLC) and then lyophilized to removing any remaining water. 
 
2.3 Circular Dichroism Spectroscopy 
 To determine the secondary structure of the S1.5 and S2.5 peptides, we employed 
circular dichroism spectroscopy with the help of Werner Tegge (Helmholtz Center for 
Infectious Research). The circular dichroism (CD) spectra of S1.5 and S2.5 were 
measured with a JASCO J-815 circular dichroism spectrometer at 20⁰C with a cell 
thickness of 0.5 mm. Each sample measured contained 100 µM peptide in 50 mM 
sodium phosphate pH 7.0. The samples were scanned at 50 nM / min with a range of 
190-300 nM. for each wavelength. 10 replicate scans were performed which were 
averaged for the resulting spectra of each peptide.  
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2.4 P81 Phosphotransfer-Assay   
 To test the kinase activity of the purified PKG and the various experimental 
conditions, a radioactive assay was adapted from the work of (Landgraf and Hofmann., 
1989) as well as (Dostmann et al., 1999). In this assay PKG performs a 
phosphotransferase reaction which transfers the terminal phosphate of a P32 tagged ATP 
molecule to the basic W15 peptide substrate that has the amino acid sequence 
TQAKRKKSLAMA (Dostmann et al., 1999). The reaction is transferred to a Whatman 
P81 phosphocellulose filter paper which binds the substrate and allows for accurate 
measurement of CPM in a liquid scintillation counter. Based on the degree of 
radioactivity, the velocity at which the kinase phosphorylates the substrate can be 
determined. Using a series of increasing concentrations of activator in each reaction we 
are able to plot the resulting velocities and determine the kinetic profile of different 
conditions and activators with respect to PKG.  
To prepare for the kinase assay, the reactions were labeled and organized in 
duplicate 1.5 mL Eppendorf tubes with blank, zero and the varying concentrations of 
cGMP. 10 µL of each 10x cGMP stock was aliquoted into their respective tubes and 
DDH2O in the blank and zero. The reaction tubes were stored at 4⁰C until it was time to 
run the reaction.  The Whatman P81 phosphocellulose filters (2cm/1.9cm) were labeled 
to their corresponding reaction number. For each reaction, 20 µL of 5xMES mix (250 
mM MES ph 6.9, 5mM MgoAC, and 50mM NaCl), 10 µL of 100 mM DTT, 10 µL of 10 
mg/mL BSA (Cohn’s fraction V), 10 µL of 100 µM W15 substrate, and 10 µL of DDH2O 
were added to a 15 mL conical on ice constituting the batch reaction mix. Prior to adding 
the ATP to the reaction mix, it had to be spiked with P32 tagged ATP.  
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To determine the specific activity of the P32 tagged ATP, 10 µL of 1mM for each 
reaction plus 50 µL was added to an separate tube then P32 tagged ATP was added with 
the rational that 1/100 * total volume (ATP) = volume P32 ATP added on the 1st day of 
receiving it and 1/50th at 1 half-life (14 days). Once the ATP was spiked 5 µL was diluted 
1:10 and then in duplicate 10 µL was blotted onto P81 filter papers and then measured in 
the liquid scintillation counter. Once the specific activity of the ATP was determined, 10 
µL for each reaction was added to the reaction mix. 70 µL of the reaction mix was added 
to each reaction tube. The reactions are activated with the addition of 20 µL of diluted 
PKG.  
 A dilution of the PKG stock was created in Enzyme Dilution Buffer (EDB) (50mM 
MES ph 6.9, 1 mg/mL BSA (cohn’s fraction V), 1 mM TCEP, and 50 mM NaCl) resulting 
in a 10x stock of PKG that corresponds to 8 ng of PKG per reaction ensuring steady state 
conditions. The reactions were initiated with 20 µL of the diluted PKG (pipetted 10 times 
for consistency), and 20 µL of ddH2O for the blank condition, resulting in a total reaction 
volume of 100 µL. The reactions proceeded at 30⁰C for 3 minutes. To terminate the 
reaction, 50 µL of the reaction was blotted onto its corresponding Whatmann P81 filter 
paper, which was then washed in 20 nM phosphoric acid 4 times to stop non-specific 
binding and remove unbound P32. The filters were dried, placed in scinti vials containing 
PPO and POPOP in toluene, and their CPM was measured via liquid scintillation counter 
(Perkin Elmer). 
 
2.4.1 S1.5 and cGMP Pre-Incubation and S-tide Analog Kinetic Assays 
The work of Thomas Moon et al., 2015, established that the binding kinetics for 
S1.5 was quite slow and that it required pre-incubation with PKG Iα in order to activate 
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it. For this reason, it was necessary to adapt the procedure from section 2.4.0 to allow 
for a 30 minute incubation prior to activation. The cGMP and S1.5 kinase assays without 
incubation were conducted with the previously stated procedure using the same set of 
reagents and timing. The cGMP and S1.5 assays with incubation were performed with the 
same reagents and concentrations but differed in the setup and initiation. To allow for a 
30 minute incubation of PKG with either S1.5 or cGMP, the 10 µL of the activator and 20 
µL of the diluted PKG were added to the reaction tube first and incubated at 30⁰C for 30 
minutes. The reactions were initiated with the addition of 70 µL of the reaction mix. The 
reactions proceeded for 3 minutes and were terminated as previously stated. This 
method of assay was used to perform the assays in which we tested the new S-tide 
analogs.  
 
2.4.2 Activator Combination Assays and PKG Iα Mutant Assays 
To test the effect of activating PKG Iα with a combination of S1.5 and cGMP, the 
procedure specified in section 1.4.1 was altered slightly allowing for pre-incubation and 
the addition of another reagent. Like 1.4.1, the activator was combined with the PKG Iα 
for a pre-incubation. In this case it contained 20 µL of the PKG dilution, 10 µL of the 
cGMP stock and 10 µL of the S1.5 stock. To compensate for the 10 µL of the second 
activator, the 10 µL of DDH2O was omitted from the reaction mix. After the 30 minute 
incubation, the reactions were initiated with 60 µL of reaction mix. The reactions 
proceeded for 3 minutes and were terminated in the same manner previously described. 
To test if S1.5 shares the same degradation of activity as cGMP when activating the C42S 
mutant, two procedures were used. To establish the kinetics of cGMP on C42S, we 
employed the same procedure as 2.4.1. A pre-incubation was needed to activate C42S 
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with S1.5 due to its slow binding kinetics. The E292A mutant was tested in the same 
manner as C42S with the addition of a combination assay, as stated previously, to 
determine the effect of the B-site knockout. 
 
2.5.0 Synthesis of P81 Phosphocellulose 
 Our protein kinase assay relies on the use of phosphocellulose paper (P81) as a 
means to trap the enzyme’s reaction product, phosphorylated substrate peptide 
(Dostmann., 2000). When the maker of P81 discontinued its product line, it became vital 
to develop a protocol for the reliable and sustainable synthesis of phosphocellulose. By 
utilizing sodium trimetaphosphate (P3m) (Figure 2.5.1) we succeeded to develop a semi-
automatic method by converting 10 x 10cm sheets of regular cellulose filter paper 
(Whatmann) at PH 12.0 and 50⁰C (Inoue., 1995). P3m reacts with hydroxyl-groups of α-
D-glucose and other sugars by a nucleophilic substitution reaction to form mostly 
monophosphate derivatives. Triphosphate derivatives will also be formed to a lesser 
degree. The reaction solution was constantly adjusted to PH 12 by addition of 6M NaOH 
solution. To assure equal reaction conditions for all paper sheets, a device was designed 
that would hold each sheet in quasi suspension (Figure 2.5.2). The device was 3D 
printed in the lab using ABS (Acrylonitrile butadiene styrene) plastic on a PRUSA I3 
MK3 printer. A Büchner funnel holding 6M NaOH and a PH electrode allowed for 
constant monitoring and addition of NaOH. After a 2 week reaction time, the 
phosphocellulose sheets were extensively washed, dried in acetone and subsequently in 
air, and cut to size (2x2 cm). A quality test revealed that our P81-paper had similar 
capacity and signal stability across all sheets. For this a PKG kinase assay was used under 
fully saturated conditions. 
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Figure 2.5.1 Structure of Sodium Tirmetaphosphate (P3m) 
Above is the structure of the sodium trimetaphosphate (P3m) used in the reaction with 
cellulose paper to result in the synthesis of phosphor cellulose.  
 
 
Figure 2.5.2 P81 Filter Production Device 
The figure above is the final design of the filter suspension system. The holder was 
designed to fit into a 2 L beaker and produces 16 8x8 filters. The bottom is raised to 
allow for a stir bar to move freely.   
 
 
 
42 
 
2.5.1  Validation of P81 Phosphocellulose 
 To determine the efficacy of the phospohocellulose produced in 2.5.0 we 
employed kinase assays with PKG 1α as described previously using 5 µM cGMP to 
achieve maximal activation. In order to test the consistency amongst all filter’s sheets 
produced in one synthesis a filter cut from the same location on all sheets were reacted 
with the same conditions. To test the consistency across the whole filter sheet, the whole 
sheet was divided into equal 2 x 2 cm and they were reacted with consistent conditions. 
To overall efficacy of the synthesis the same kinase assay was performed testing our 
filters against Whatman P81 filters we had saved for this purpose.   
2.6 Data Analysis 
 In order to interpret the data collected from the various experiments conducted 
in this thesis several programs were employed to covert raw experimental data into 
usable kinetic information. When the kinase assay is performed we obtain counts per 
minute (CMP) from the liquid scintillation counter. This data is imported into excel 
where the average velocity minus the blank is calculated of two replicate counts. The 
velocity is calculated by multiplying the CMP by the blotting and purity correction and 
dividing by the reaction time, concentration of protein and the specific activity. This 
results in the velocity (µmol(P-W15) / min x mg (PKG)). The velocities and their 
corresponding activator concentrations are then imported into Graphpad Prism™ where 
a nonlinear regression curve fit is performed on velocity vs Log concentration to 
calculate the kinetic constants KA, nh, Vmax, Vmin and fold activation. The non linear 
curve fit generates the accompanying graphs seen throughout this thesis. 
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3.0 RESULTS 
3.1 Protein Expression and Purification 
 To explore the objectives of this thesis it was necessary to express and purify 
recombinant PKG Iα wild type as well as the various mutant forms of PKG. The Bac to 
Bac baculovirus protein expression system (Invitrogen) was employed because bacterial 
expression of PKG Iα has yet to be accomplished (Feil et, Al., 1993). Wild type PKG Iα as 
well as all typesof mutant forms of PKG expression and purification has been developed 
in the Dostmann Lab (Dostmann et,al., 2000; Sheehe., 2018). Likewise the expression 
the of the mutant forms of PKG Iα E292A and C42S was performed using this 
established protocol. 
 Following lysis and Ni2+ affinity chromatography, a correlative Bradford assay 
was performed on each of the elution samples to determine which fraction contained the 
protein (Figure 3.1.1). To further establish purity of the enzyme preparations, gel 
electrophoresis using 1mm 4-20% TGX gel, were performed on the clarified lysate (CL), 
flow through (FL), first wash (W1), second wash (W2), elution 3 (E3), and elution 4 (E4) 
(Figure 3.1.2.). From the pooled and dialyzed fractions, the concentrations and total 
yields were determined (Figure 3.1.3). Lastly, to determine if the resulting PKG Iα 
enzymes were pure and functional, a Kinase assay was performed on wild type with 
varying concentrations from 2 nM – 10 µM of cGMP. The resulting data was subjected to 
a non linear regression curve fit to determine the kinetic characteristic of the enzyme 
(Figure 3.1.4., Table 3.1.1). The total yields for the expressions for PKG Iα WT, 
E292A, and C42S were 14.2 mg, 5.4 mg, and 10 mg, respectively. The resulting activity 
with cGMP was consistent with previously determined data. 
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Figure 3.1.1. Correlative Bradford analysis of PKG Iα WT purification 
Fractions. 
This figure displays the results of combining 5 µL of elution fraction to 1 mL of Bradford 
reagent. The analysis is sequentially elution fractions 1-6. The color change is dependent 
of the presence of protein from changing from brown to blue when protein is added. 
 
  
Figure 3.1.2. Gel electrophoresis of PKG Iα WT purification steps. 
The gel above is the result of running 15 µL of sample from each step of the Ni affinity 
chromatography performed on the cellular lysate of sf9 cells expressing PKG Iα WT and 
5 µL of protein ladder on a 1mm 4-20% TGX protein gel for 30 minutes at 190 V and 
0.68A. From left to right the columns were as follows; protein ladder, clarified lysate 
(CL), flow through (FL), wash 1 (W1), wash 2 (W2), ladder, elution 3 (E3), and elution 4 
(E4). 
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Figure 3.1.3. Test activation of PKG Iα wild type prep with cGMP. 
Above is a nonlinear regression curve fit of cGMP activated PKG Iα WT (N=2). The curve 
was created with individual reaction velocity’s from 9.3 ng of PKG Iα, varying 
concentrations of cGMP 2nM – 10 µM and reaction times of 3 minutes. The x-axis 
displays the log concentration of cGMP and the Y-axis is the reaction velocity in µ mols 
of phosphorylated w15 substrate per minute mg of PKG Iα. 
 
 cGMP 
Vmax (µmol x min-1 x mg-1) 7.6 ± 0.05 
Vmin (µmol x min-1 x mg-1) 0.34 ± 0.044 
Fold Activation 22.4 
nh 1.58 ± 0.06 
Ka (µM) 0.13 ± 0.064 
 
Table 3.1.1. Kinetic constants derived from the non linear regression fit of 
the cGMP PKG Iα activation curve. 
Displayed are the kinetic variables determined from the kinetic analysis in Figure x. 
The experimental conditions are listed in the top row and their corresponding kinetics 
are in their respective columns. Vmax corresponds the maximal velocity of each curve, nh 
corresponds to the hill coefficient of the curve, and the Ka is the activation constant of 
each curve. 
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3.2 Determination of optimal Activation Conditions for S-tide Activation 
of PKG-Iα 
 The work of Moon et al. (2015) explored the idea of synthetic peptides activators 
of PKG Iα derived from the recently discovered switch helix domain and determined the 
S1.5 peptide (YEDAEAKAYEAEAAFANLKLSD) to be the most active. While studying the 
peptides binding kinetics it was discovered that it required extended incubation with 
PKG Iα to reach maximal binding. This determines the need for a preincubation of the S-
tides with PKG prior to kinetic analysis. This addition to the established P81 phosphoryl 
transfer assay warranted experimentation to determine the effect that preincubation has 
on PKG Iα wt so that the S1.5 analysis can be deemed valid. It was hypothesized that an 
incubation of 30 minutes at 30⁰C would result in ample time for S-tide binding and 
would not result in any negative effect on the enzyme itself. To test this hypothesis, 
kinetic assays were performed on PKG-Iα WT with both cGMP and S1.5 comparing 
preincubation and no preincubation. The resulting data by plotting reaction velocity 
against the Log concentration of activator with a four-parameter nonlinear regression 
curve fit (Graph pad Prism). Below, the combination graph displaying each condition as 
well as the table with their respective Vmax, activation constant (Ka), and hill coefficient 
(nh) (Figure 3.2.1., Table 3.2.1). This data shows that there is no effect on the 
activation profile when the enzyme was activated with cGMP supported by the Vmax of 
about 4 µmol(w15-p)/min*mg and a Ka of about 100µM for both trials, which is in 
agreement with the published values. Conversely preincubation greatly improved the 
activation of S1.5. As for the S1.5 the no preincubation trial resulted in an activation 
profile that could not reach maximal velocity at testable concentration, the preincubation 
S1.5 resulted in hill coefficient (nh) of 2.5 and activation constant (Ka) of about 6 µM 
which is consistent with previous data (Moon., 2015). 
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Figure 3.2.1. Activation curves comparing cGMP V.S. S1.5 and preincubation 
V.S. no incubation (N=4,2,8,6 respectively).  
The reported Y-axis units are velocity in µmols of phosphorylated substrate (w15-p) per 
minute mg of PKG-Iα and X-axis units are logarithmic molar concentration of activator 
(cGMP and S1.5). The increasing concentrations were plotted in order resulting in a 
sigmoidal curve of PKG-Iα activation. 
 
 
Table 3.2.1. Kinetic constants derived from the activation curves comparing 
cGMP V.S. S1.5 and preincubation vs no Pre-incubation. 
Displayed are the kinetic variables determined from the kinetic analysis in Figure 3.2.1. 
The experimental conditions are listed in the top row and their corresponding kinetics 
are in their respective columns. Vmax corresponds the maximal velocity of each curve 
[µmol x min-1 x mg-1], nh corresponds to the hill coefficient of the curve, and the Ka is the 
activation constant of each curve. 
 cGMP 
Preincubation 
cGMP  
no 
Preincubation 
S1.5 
Preincubation 
S1.5 no 
preincubation 
Vmax 4.04 ± 0.022 4.0 ± 0.015 2.31 ± 0.034 - 
Vmin 0.65 ± 0.024 0.44 ± 0.014 0.65 ± 0.041 - 
Fold 
Activation 
6.2 9.1 3.6 - 
nh 1.6 ± 0.06 1.5 ± 0.031 2.5 ± 0.34 - 
Ka [µM] 0.11 ± 0.06 0.14 ± 0.043 5.9 ± 0.72 - 
48 
 
 
3.3 Comparing the Activation Kinetics of S-tide Analogs 
 Following the discovery that the switch helix can activate PKG-Iα, synthetic 
peptides were created to explore the necessary amino acid residues for optimal activation 
resulting in the S1.5 peptide (see section 3.2.) (Moon et al., 2011, 2015). We worked to 
further develop the S-tides and target the adjacent cGMP Bite. As part of this study, it 
was concluded that intermediary peptide was needed to test the removal of the L, S, and 
D of the S1.5 followed by the addition of a cysteamine linker to increase the binding, the 
peptides were named S2.5 and S3.5 respectively (Figure 3.3.1). The hypothesis was that 
the removal of the terminal LSD of S1.5 (S2.5) and the addition of the linker (S3.5) would 
not alter the kinetics of activation of PKG-Iα. Kinase assays were performed on S1.5, S2.5 
and S3.5 and a nonlinear regression curve fit was performed on the resulting data by 
plotting the reaction velocity against the logarithm of activator concentration allowing 
for calculation of the Vmax, Ka, and nh (Figure 3.3.2., Table 3.3.1). The results of the 
S2.5 trials show a significant shift in the activation to the right meaning the activity of 
the peptide is decreased from what is seen with S1.5. The S3.5 activation was shifted even 
further, meaning it is even less active and that the addition of the linker further degrades 
the activity seen in S2.5. when comparing the kinetic constants of all of these S-tides the 
degradation of activity is seen with the sequential increase in concentration needed to 
reach the Ka; 5.9 µM, 15 µM, and 73 µM for S1.5, S2.5 and S3.5 respectively. A surprising 
result from this experiment is that the Vmax from S1.5: 2.3 µmol(w15-p)/min*mg was 
severely degraded with the S2.5 modification: 1.6 µmol(w15-p)/min*mg. This 
degradation of efficacy seems to be fixed by the addition of the linker in S3.5: 2.7 
µmol(w15-p)/min*mg, this points to the need of a protecting group at the end of the S-
tide. The lack of knowledge of how the holoenzyme is activated warrants further 
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exploration. We hypothesized that the removal of the C-terminal LSD could cause helical 
instability and prompted secondary structure analysis of the peptide. 
It has been determined that the helicity of the S-tides derived from the switch 
helix was a crucial factor for activation of PKG Iα (Moon et al., 2015). It was concluded 
that shortening of the S-tides via the C-terminus could disrupt the helicity of the peptide 
rendering less active. The decrease in activity from S1.5 to S2.5 warranted exploration 
into the structure of S2.5 and specifically the helical nature of the peptide which has been 
recognized as a critical part of its function. It was hypothesized that helical instability 
was the cause of S2.5’s impaired activation kinetics. To test this circular dichroism 
spectroscopy was performed on S2.5. S1.5 was used as a control due to its known helical 
stability. The secondary structure analysis by circular dichroism spectroscopy results in 
different characteristic traces based on the secondary structure of the peptide being 
analyzed, an alpha helix will result in a peak at about 190 nm  followed by two 
consecutive troughs at 205 and 220 nm, a beta sheet will be represented by an initial 
peak at about 200 nm and a long sloping trough that terminates at 220 nm, as for a 
random coil the trace would show a trough at 200 nm and peak at 220 nm (Bulheller et 
al., 2007). The resulting data was graphed, and the two resulting curves were analyzed to 
determine the difference in helicity. The helical structure of S2.5 is seen to be almost the 
same as S1.5 (Figure 3.3.3), the traces display near identical alpha helix trace 
characteristics as mentioned earlier, and therefore doesn’t explain the shift in activation. 
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Figure 3.3.1. Structure of S2.5 and S3.5 
Displayed above are the structures of the S1.5 analogs S2.5 and S3.5 denoted from N to 
C. The N-terminus of these peptides have an acetyl group conjugated onto it protecting 
the terminus. The C-terminus of the S2.5 peptide has an amino group attached to protect 
the terminus. 
 
 
 
Figure 3.3.2. Activation Curves Comparing the Kinetics of S1.5, S2.5, and 
S3.5 
The reported Y-axis units are velocity in µmols of phosphorylated substrate (w15-p) per 
minute mg of PKG-Iα and X-axis units are logarithmic molar concentration of activator 
(S1.5, S2.5, and S3.5). The increasing concentrations were plotted in order resulting in a 
sigmoidal curve of PKG-Iα activation with cGMP control at 5 µM. 
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 S1.5 S2.5 S3.5 
Vmax 
(µmol x min-1 x mg-1) 
2.31 ± 0.034 1.64 ± 0.021 2.8 ± 0.25 
Vmin 
(µmol x min-1 x mg-1) 
0.65 ± 0.041 0.37 ± 0.01 0.49 ± 0.021 
Fold Activation 3.6 4.5 5.8 
nh 2.5 ± 0.34 3.2 ± 0.22 1.9 ± 0.26 
Ka [µM] 5.9 ± 0.73 14.5 ± 0.07 73.1 ± 2.8 
 
Table 3.3.1. Kinetic constants derived from activation curves comparing 
S1.5, S2.5, and S3.5 activation of PKG Iα. 
Displayed are the kinetic variables determined from the kinetic analysis in Figure 
3.3.2. The experimental conditions are listed in the top row and their corresponding 
kinetic variables are in their respective columns. Vmax corresponds the maximal velocity 
of each curve, nh corresponds to the hill coefficient of the curve, and the Ka is the 
activation constant of each curve. 
 
 
Figure 3.3.3. Circular Dichroism Helical Profile of S1.5 and S2.5 
The graph plots mean residue ellipticity (θ) mdeg (y-axis) vs the measured wavelength 
(λ) in nm (x-axis). The data points are plotted with increasing measured λ. The difference 
line denoted by the triangular points represent the difference between the S1.5 and S2.5 
data points.  
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3.4 PKG Iα Co-Activation and Activation Site Interplay. 
 Our original hypothesis on the mode of activation of S-tides and cGMP proposed 
a linkage since the SW nest shares residues with the cGMP B-site. However, our findings 
from the PKG Iα C42A trials suggest this may not be the case and prompted further 
exploration. To further explore the potential interplay between the S1.5 and cGMP 
binding sites we studied the kinetics of co-activation between the two. We hypothesized 
that co activation would result in a synergistic activation of PKG Iα, if the sites of 
activation are linked. To test this hypothesis a series of experiments were devised with 
the rational of performing kinetic assays of cGMP and S1.5 but with the addition of half 
maximal velocity levels of the other activator. The cGMP assays were performed with 
varying cGMP concentrations and a constant concentration of S1.5 at 1 µM. The S1.5 
assays were performed with varying S1.5 concentrations and a constant concentration of 
cGMP of 100 nM. The resulting data was analyzed by plotting the velocity vs log agonist 
concentration with a nonlinear regression curve fit to determine the activation kinetics 
(Figure 3.4.1. Table 3.4.1.) The resulting graph shows that the cGMP + 1 µM S1.5 had 
little effect on the overall kinetic profile compared to cGMP alone with a slight shift in 
the Ka from about 100 nM to about 140 nM. The addition of 100 nM cGMP to S1.5 
resulted in extremely high basal activity of about 50% activation which is expected when 
using half maximal cGMP. We also saw a shift of Ka from about 5 µM to about 12 µM. 
This decrease in potency is contrary to the idea of synergism but when comparing the 
Vmax of this trial to S1.5 alone we see that the combination assay resulted in 80% 
maximal activation whereas normally we would only see about 60% activation. This 
points to the combination causing a decrease in potency but an increase in efficacy. A 
potential cause of the decrease in potency could be that the cGMP B-site may not be a 
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site of activation but rather a site of regulation for the SW nest site. This idea prompted 
us to use more mutant models to explore this possibility even further.  
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Figure 3.4.1. Co-Activation curves of cGMP + S1.5 and S1.5 + cGMP. [N=4] 
The reported Y-axis units are normalized percentage of maximal velocity of µmols of 
phosphorylated substrate (w15-p) per minute mg of PKG-Iα, The S1.5 + cGMP was 
calculated from a 5 µM cGMP control run at the end of the data set. The X-axis units are 
logarithmic molar concentration of activator (cGMP and S1.5). The cGMP curve, denoted 
by the circular data points, had a constant concentration of S1.5 of 1 µM in every 
reaction. The S1.5 curve, denoted by the triangular data points, had a constant 
concentration of cGMP of 100 nM in every reaction. These curves detail the coactivation 
of PKG 1α. 
 cGMP + 1µ S1.5 S1.5 + 100 nM cGMP 
Vmax 
(µmol x min-1 x mg-1) 
100% ± 0.33 80.38% ± 1.97 
Vmin 
(µmol x min-1 x mg-1) 
12.2% ± 0.29 49.4% ± 1.05 
Fold Activation 8.2 1.63 
nh 1.61 ± 0.034 1.9 ± 0.45 
Ka [µM] 0.14e-7 ± 0.04 12.4 ± 0.34 
 
Table 3.4.1. Kinetic constants derived from the activation curves comparing 
co-activation of PKG 1α with S1.5 and cGMP. 
Displayed are the kinetic variables determined from the kinetic analysis in Figure 
3.6.1. The experimental conditions are listed in the top row and their corresponding 
kinetics are in their respective columns. Vmax corresponds the percentage of maximal 
cGMP velocity of each curve, nh corresponds to the hill coefficient of the curve, and the 
Ka is the association constant of substrate binding for each curve. 
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3.5 Activation of PKG Iα E292A mutant with cGMP and S1.5 
 To elucidate the interaction between S-tide and cGMP activation it was 
determined a mutant protein model where the cGMP B-site was knocked out would give 
valuable insight into the effect cGMP binding to the B-site has on the activity of S-tides. 
The rational for this is that it has been theorized that due to the proximity of the B-site 
and the switch helix binding site there is site activation interplay. We wanted to test first 
the effect the E292A mutant would have on normal activation via cGMP and S1.5 when 
compared to PKG Iα WT. Therefore, we performed kinase assays where E292A was 
activated with cGMP and S1.5. Secondly, we wanted to see what the direct interplay 
would be if we co-activated the E292A mutant. This experiment is in response to the 
results of the experiments were we coactivated PKG Iα WT, it was thought there would 
have been synergism but what we saw was the opposite. This lead us to the idea that 
cGMP binding to the B-site might be interfering with the switch helix binding site. To 
test this, we employed the E292A mutant in a co-activation assay to see if the effect is 
rectified by the knockout of the B-site. The assays were conducted with constant 
concentration of one of the activators at half maximal concentration and then a full 
activation curve of the other activator.  
 The resulting data was graphed and was subjected to a nonlinear regression curve 
fit to determine each conditions kinetics (Figure 3.5.1., Table 3.5.1). When comparing 
the kinetics of the cGMP and S1.5 activation of E292A with that of PKG Iα WT (Table 
3.5.1.) it is seen that there is no significance change in the kinetic constants. The 
combination assay where there was 1 µM S1.5 and varying concentration of cGMP the 
resulting activation curve has a slight decrease in Vmax; from 3.021 to 2.56 (µM(W-15 
and hill slope potentially. The combination assay in which we had a constant 100 nM 
cGMP and varying S1.5 concentration we saw a very high basal activity of about half 
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maximal which is consistent to the wild type combination experiments. This experiment 
also resulted in a shifted activation in which the Vmax was not able to be reached at the 
concentrations we tested and therefore a significant Ka could not be calculated but seems 
to be around 100 µM. This also points to a higher Vmax as well pointing to an increase in 
activity when compared to S1.5 activating E292A by itself which is consistent to the wild 
type combination assays.  
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Figure 3.5.1. Co-Activation of PKG Iα E292A with cGMP [N=4], S1.5 [N=4], 
cGMP + S1.5 [N=2] and S1.5 + cGMP [N=2] 
The reported Y-axis units are velocity in µmols of phosphorylated substrate (w15-p) per 
minute mg of PKG-Iα and X-axis units are logarithmic molar concentration of activator 
(S1.5 and cGMP). The increasing concentrations were plotted in order resulting in a 
sigmoidal curve of PKG-Iα E292A activation in the presence of cGMP, S1.5, cGMP + 1 
µM S1.5, S1.5 + 100 nM cGMP. 
 
 cGMP S1.5 cGMP + 1µM 
S1.5 
S1.5 + 100 
nM cGMP 
Vmax 
(µmol x min-1 x mg-1) 
3.02 ± 0.012 1.98 ± 0.06 2.56 ± 0.031 - 
Vmin 
(µmol x min-1 x mg-1) 
0.08 ± 0.012 0.19 ± 0.07 0.21 ± 0.03 - 
Fold Activation 35.96 10.63 12.2  
nh 1.45 ± 0.03 2.31 ± 0.44 1.51 ± 0.11 - 
ka [µM] 0.10 ± 0.04 2.93 ± 0.69 0.12 ± 0.13 - 
 
Table 3.5.1. Kinetic constants derived from the activation curves comparing 
co-activation of PKG Iα E292A with S1.5 and cGMP 
Displayed are the kinetic variables determined from the kinetic analysis in Figure 
3.6.1. The experimental conditions are listed in the top row and their corresponding 
kinetics are in their respective columns. Vmax corresponds the percentage of maximal 
cGMP velocity of each curve, nh corresponds to the hill coefficient of the curve, and the 
Ka is the association constant of substrate binding for each curve. 
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3.6 Efficacy of S1.5 Activation of the Mutant PKG Iα C42S  
 Due to the proximity of the Switch helix binding site to the cGMP B-site it was 
hypothesized that the cGMP binding site-B and the S-tide binding site (nest) interact. To 
explore this potential interaction, we determined that mutant enzyme models would be 
an effective experimental approach. The C42S mutant form of PKG Iα has been 
determined to have diminished activation kinetics with cGMP, demonstrating that the 
mutation disrupts the pathway in which cGMP activates the enzyme (Sheehe et.al., 
2018). We incubated this enzyme with S1.5 to test its activation kinetics. If the two sites 
communicate, the activation kinetics for S1.5 with C42S would display the marked shift 
in Vmax and Ka. To test this hypothesis a series of kinetic assays were performed 
comparing the activity of S1.5 and cGMP.  Statistical analysis was performed on the 
resulting data by plotting reaction velocity against the logarithm of activator 
concentration with a nonlinear regression curve fit to determine the kinetic profile of 
each type of activation. Shown below are a graph and a table displaying the activation 
curve and the kinetic variables calculated resulting from the experiments. (Figure 
3.6.1., Table 3.6.1.) PKG C42S shows a remarkable decline in kinetic activity as 
previously reported (Sheehe et.al., 2018). Not only the Ka for cGMP is shifted 3-fold 
shifted from 140 µM (WT) to 450 µM (C42S), the Vmax is also 2-fold reduced from 4 
µmol(W15-p)/min*mg(PKG) to 2 µmol(W15-p)/min*mg(PKG). Taken together the 
overall catalytic activity of C42S is less than 10% compared to WT at half maximal 
activity and approximately 30-50% of full strength of WT. these findings are in 
agreement with our previously published values. In contest however, the activation 
kinetics of S1.5 are indistinguishable between C42S and WT. Apparently S1.5 activates 
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C42S with the same potency and efficacy from WT. These results indicate that the S1.5 
binding site operates independently from the cGMP mediated mechanism of action. 
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Figure 3.6.1. Activation curves comparing cGMP (N=2) and S1.5 (N=6) with 
the PKG Iα C42S mutant V.S. cGMP (N=6) and S1.5 (N=8) activation of PKG 
Iα WT.  
The reported Y-axis units are velocity in µmols of phosphorylated substrate (w15-p) per 
minute mg of PKG-Iα and X-axis units are logarithmic molar concentration of activator 
(S1.5 and cGMP). The increasing concentrations were plotted in order resulting in a 
sigmoidal curve of PKG-Iα C42S mutant and wild type activation. The red curves 
represent wild type activation and blue represents C42S activation. 
 
 cGMP WT S1.5 WT S1.5 C42S cGMP C42S 
Vmax 
(µmol x min-1 x mg-1) 
4.0 ± 0.01 2.31 ± 0.03 2.04 ± 0.02 2.41 ± 0.04 
Vmin 
(µmol x min-1 x mg-1) 
0.44 ± 0.01 0.65 ± 0.04 0.11± 0.02 0.08 ± 0.04 
Fold Activation 9.05 3.29 19.07 31.32 
nh 1.48 ± 0.03 2.48 ± 0.34 2.23 ± 0.13 1.67 ± 0.13 
Ka [µM] 0.14 ± 0.04 5.86 ± 0.73 4.49 ± 0.29 0.46 ± 0.53 
Table 3.6.1. Kinetic constants derived from the activation curves comparing 
cGMP and S1.5 activation of PKG Iα C42S mutant. 
Displayed are the kinetic variables determined from the kinetic analysis in Figure 3.5.1. 
The experimental conditions are listed in the top row and their corresponding kinetic 
variables are in their respective columns. Vmax corresponds the maximal velocity of each 
curve, nh corresponds to the hill coefficient of the curve, and the Ka is the activation 
constant of each curve.  
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4.0 DISCUSSION AND FUTURE DIRECTIONS 
 In this thesis we explored the necessary conditions for the concerted activation of 
PKG Iα using cGMP and peptide analogs derived from the SW domain with the goal to 
prove or disprove the structure activity relationship between the nucleotide and peptide 
binding sites. To accomplish these goals, we employed site-specific mutagenesis, 
secondary structure analysis via circular dichroism spectroscopy, and protein kinase 
activity assays using the P81 phosphoryl transfer assays. As a result we determined the 
optimal conditions for kinetic assays, we uncovered the kinetic profile of new PKG Iα 
activators and gained detailed insights into the complex interaction between switch helix 
and cGMP mediated activation of PKG Iα. 
 The first portion of this thesis was devoted to understanding the requirements of 
activating PKG Iα with S-tides in relationship to cGMP. Through surface plasmon 
resonance analysis of S-tide association kinetics it was discovered that S-tides require at 
least 10 minutes to reach peak bound state (Moon et.al., 2015). This discovery warranted 
an adaptation of the P81 phosphoryl transfer assay where we implemented a 30-minute 
preincubation at 30⁰C (reaction temperature) to ensure full binding of the S-tide for 
each reaction. We compared the cGMP and S1.5 activation with and without the 
preincubation and determined that the addition of preincubation did not affect cGMP 
activation but was necessary for S1.5 activation. 
 After the discovery of the switch helix domain of PKG and S-tide activators the 
idea of using this as a novel drug target was the logical progression for the Dostmann 
laboratory. S1.5 is the most potent switch helix analog to date, discovered through 
careful N and C-terminal truncations, further shortening of the peptide resulted in 
decreased activity, therefore building upon this peptide was the next step in improving 
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activity (Moon et.al, 2015). Molecular modeling was employed to determine the structure 
of a peptide that would interact with the switch helix binding site and the adjacent cGMP 
B-site. We determined there was a need for intermediary peptides with sequential C-
terminus modification. These consisted of S1.5 minus the three C-terminal amino acids 
(S2.5) and the addition of a cysteamine linker (S3.5) (Figure 3.3.1). Both peptides 
resulted in sequential rightward shifts in Ka meaning they had decreased activity. This 
was contrary to the hypothesis. We employed secondary structure analysis of S2.5 and 
S1.5 to determine if the subtraction of the amino acids was affecting the α-helicity of the 
peptides, we determined it was not. Therefore, we cannot explain the decreased activity 
that easily.  These results have caused us to rethink the possible role of the B-site in S-
tide activation and caused us to peruse structural analysis of the B-site with regards to S-
tide activation to elucidate what is happening.  The S3.5 peptide requires further 
exploration and we have concluded experimentation with S3.5 and mutant forms of PKG 
Iα would serve as way to increase our understanding of the B-site and S-tide activation. 
We would also like to follow these experiments with surface plasmon resonance assays to 
determine if S2.5 and S3.5 have different binding and dissociating kinetics than S1.5 
which could help explain the shift in the data. 
Once we established the need for more exploration of the B-site with respect to 
S1.5 activation we determined a set of experiments employing activator combination 
assays and mutant forms of PKG Iα would give us valuable insight into the mechanisms 
at play. To determine the co-dependency between the two mechanisms we performed 
combination assays where we used both activators to activate PKG Iα WT. The results of 
this experiment showed high basal activity and decrease in potency via a rightward shift 
in the Ka when cGMP was added to an S1.5 assay. These results point to some 
interference between the two pathways of activation. The interference may be caused by 
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a conformational change of PKG that effects switch helix activity. This led us to believe 
that the cGMP B-site is potentially acting as a site of regulation for the switch helix 
binding site and prompted us to use the E292A mutant form of PKG Iα which is a B-site 
knock out to determine the role of the B-site when performing a combination assay. We 
devised a series of experiments with the E292A mutant first to determine the kinetics of 
cGMP and S1.5 activation with this mutant followed by activator combination assays. 
The results of the normal activations established that the E292A mutation does not affect 
either form of activation compared to PKG Iα WT. The combination assay results showed 
that the cGMP + s1.5 experiment was not affected by the mutation but the S1.5 + cGMP 
experiment showed an even more significant decrease in potency from the WT 
combination assay. This is contrary to the hypothesis that the B-site is affecting switch 
helix binding, if this was the case the Ka would not have been shifted. This data set only 
represents an N=2 due to a world-wide shortage of the filter paper that this assay is 
based off and therefore requires further testing. In the future this assay will be repeated 
and with higher S1.5 concentrations to reach maximal activity so the kinetic profile could 
be more accurately evaluated. We would like to follow this up with the E167A mutant 
which is being produced at the time of this thesis completion. E167A is an A-site 
knockout which is a dead enzyme, if S1.5 can activate E167A it would support the 
findings that S1.5 activation is rather cGMP independent.  
To help determine if the cGMP and S1.5 activation mechanisms are co-dependent 
is we used the C42S mutant form of PKG Iα, which has a known degradation of cGMP 
activation when compared to PKG Iα WT. We performed kinase assays and determined 
that the S1.5 activation was normal and was not affected like cGMP. This result shows 
supports the rejection of the central hypothesis and the idea that S-tide mediated 
activation is cGMP independent. 
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This research serves as a platform for future drug development in the critical field 
of cardiovascular health. PKG is known for its role in smooth muscle relaxation and is 
the primary effector of the nitric oxide pathway. The nitric oxide pathway has been a 
major target for antihypertension drugs since the advent of the nitro glycerin 
therapeutics. PKG would be a prime target for this purpose but due to localization in 
other areas of the body the problem of off target effects has been the major deterrent. 
The discovery of the S-tides used in this work serve to be the first isoform specific drug 
target for PKG Iα which would localize the effect of PKG activation to vascular smooth 
muscle. The further development of these S-tides could usher in a new class of 
antihypertension agents.  
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